Comment
. 2011 May;13(5):558-9; author reply 561-2.
doi: 10.1093/neuonc/nor048.
Convection-enhanced delivery of a transforming growth factor-beta2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142)
- PMID: 21558078
- PMCID: PMC3093343
- DOI: 10.1093/neuonc/nor048
Item in Clipboard
Comment
Convection-enhanced delivery of a transforming growth factor-beta2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142)
Neuro Oncol.
2011 May.
No abstract available
Comment on
-
Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.Neuro Oncol. 2011 Jan;13(1):132-42. doi: 10.1093/neuonc/noq142. Epub 2010 Oct 27. Neuro Oncol. 2011. PMID: 20980335 Free PMC article. Clinical Trial.
Similar articles
-
Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).Neuro Oncol. 2011 May;13(5):559-60; author reply 561-2. doi: 10.1093/neuonc/nor046. Neuro Oncol. 2011. PMID: 21558079 Free PMC article. No abstract available.
-
Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.Neuro Oncol. 2011 Jan;13(1):132-42. doi: 10.1093/neuonc/noq142. Epub 2010 Oct 27. Neuro Oncol. 2011. PMID: 20980335 Free PMC article. Clinical Trial.
-
Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides.Expert Rev Anticancer Ther. 2009 Nov;9(11):1663-74. doi: 10.1586/era.09.138. Expert Rev Anticancer Ther. 2009. PMID: 19895249 Review.
-
Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2.IDrugs. 2009 Jul;12(7):445-53. IDrugs. 2009. PMID: 19579166
-
TGF-β2 signaling in high-grade gliomas.Curr Pharm Biotechnol. 2011 Dec;12(12):2150-7. doi: 10.2174/138920111798808347. Curr Pharm Biotechnol. 2011. PMID: 21619538 Review.
Cited by
-
Heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial.Neuro Oncol. 2014 May;16(5):758-9. doi: 10.1093/neuonc/nou054. Epub 2014 Apr 10. Neuro Oncol. 2014. PMID: 24729070 Free PMC article. No abstract available.
-
The future of high-grade glioma: Where we are and where are we going.Surg Neurol Int. 2015 Feb 13;6(Suppl 1):S9-S44. doi: 10.4103/2152-7806.151331. eCollection 2015. Surg Neurol Int. 2015. PMID: 25722939 Free PMC article.
-
Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond.Neurotherapeutics. 2019 Apr;16(2):319-347. doi: 10.1007/s13311-018-00702-3. Neurotherapeutics. 2019. PMID: 30644073 Free PMC article. Review.
-
Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma.Cells. 2024 Nov 11;13(22):1869. doi: 10.3390/cells13221869. Cells. 2024. PMID: 39594617 Free PMC article. Review.
-
Targeting TGF-β Signaling for Therapeutic Gain.Cold Spring Harb Perspect Biol. 2017 Oct 3;9(10):a022301. doi: 10.1101/cshperspect.a022301. Cold Spring Harb Perspect Biol. 2017. PMID: 28246179 Free PMC article. Review.
References
-
- Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572–2578. - PubMed
-
- Wick WW, Weller M Neuro-oncology Working Group of the German Cancer Society. NOA-04 randomized Phase III study of sequential radiochemotherapy of oligoastrocytic tumors of WHO-grade III with PCV or temozolomide. J Clin Oncol. 2010;28(15S):5874–80.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
